scPharmaceuticals Inc. has reported recent developments, including a market capitalization of $243.6 million and a stock price of $4.85, as the company continues to focus on developing innovative treatments for heart failure and related conditions.

scPharmaceuticals Inc. is making significant strides in treating heart failure with its innovative subcutaneous furosemide and cephalosporin antibiotic products, positioning the company for growth and success in the pharmaceutical sector.